Negara: Irlandia
Bahasa: Inggris
Sumber: HPRA (Health Products Regulatory Authority)
CEFRADINE
Bristol-Myers Squibb Pharmaceuticals Ltd
250/5 Mg/Ml
Powder for Oral Suspension
1977-04-01
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Velosef Syrup 250 mg/5ml, Powder for oral suspension. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION When reconstituted contains 250 mg cefradine per 5 ml Excipients: Each 5ml contains 2.8g of sucrose _For a full list of excipients, see section 6.1_ 3 PHARMACEUTICAL FORM Powder for oral suspension. White to pale cream, moderately coarse powder. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS In the treatment of infections of the urinary, respiratory and of the skin and soft tissues. These include: Upper respiratory infections – pharyngitis, sinusitis, otitis media, tonsillitis, laryngo-tracheo bronchitis. Lower respiratory infections – acute and chronic bronchitis, lobar and bronchopneumonia. Urinary tract infections – cystitis, urethritis, pyelonephritis. Skin and soft tissue infections – abscess, cellulitis, furunculosis, impetigo Cefradine has been shown to be effective in reducing the incidence of postoperative infections in patients undergoing surgical procedures associated with a high risk of infection. It is also of value where postoperative infections would be disastrous and where patients have a reduced host resistance to bacterial infections. Protection is best ensured by achieving adequate local tissue concentrations at the time contamination is likely to occur. Thus, cefradine should be administered immediately prior to surgery and continued during the postoperative period. Bacteriology studies to determine the causative organisms and their sensitivity to cefradine should be performed. Therapy may be instituted prior to receiving the results of the sensitivity test. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Cefradine may be given without regard to meals. Adults and children over 10 years: For uri Baca dokumen lengkapnya